Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CARBON DIOXIDE, USP | — | 2013-07-05 | fda.gov ↗ |
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07420530 | Apr 2026 → Jan 2032 expected | laryngeal disorder | Indiana University | Recruiting | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT04738136 | Sep → Oct 2021 | COVID-19 | SolAeroMed Inc. | Suspended | No outcome recorded Stop: Business |
| Phase 2 | NCT04949386 | Sep → Dec 2021 | COVID-19, long COVID-19 | SolAeroMed Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT02473016 | Sep 2015 → Mar 2017 | trigeminal neuralgia | Capnia, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02381795 | Jul 2015 → Apr 2017 | cluster headache syndrome | Cady, Roger, M.D. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02113449 | Nov 2013 → Feb 2014 | nasal cavity disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00917111 | Jul → Oct 2009 | seasonal allergic rhinitis | Capnia, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00917020 | Jul → Oct 2009 | seasonal allergic rhinitis | Capnia, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00690716 | Aug 2008 → Jun 2009 | migraine disorder | Capnia, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00484029 | Feb 2007 → Oct 2008 | headache disorder, temporomandibular joint disorder | Capnia, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00325312 | Jan 2001 → Mar 2003 | spondylosis, cervical | Forschungsinstitut für Balneologie und Kurortwissenschaft Bad Elster | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03287687 | Nov 2017 → Apr 2019 | — | Warren Bishop | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00719342 | Jul 2008 → May 2009 | — | Medical University of Vienna | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02334553 Comparator | Feb → Nov 2015 | asthma | SolAeroMed Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | carbon dioxide | “S-1226 contains a potent, safe and well-tolerated bronchodilator gas (extrinsic carbon dioxide or CO2) and perflubron (PFOB), a synthetic surfactant that facilitates...” NCT04949386 ↗13“This multi-center, adaptively randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of a nasal, non-inhaled administration of carbon dioxide...” NCT00690716 ↗ “The purpose of this study is to evaluate the effect of four times a day treatment with nasal carbon dioxide in patients with Seasonal Allergic Rhinitis symptoms.” NCT00917111 ↗ “It contains a potent bronchodilator gas (carbon dioxide or CO2) and nebulized perflubron (a synthetic surfactant possessing mucolytic properties).” PMID 29914544 ↗ Jun 2018 “The Effect of Nasal Carbon Dioxide (CO2) Used As-Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis” NCT00917020 ↗ “Mixture of 92 % oxygen and 8 % carbon dioxide for inhalation” NCT00719342 ↗ “extrinsic carbon dioxide or CO2” NCT04738136 ↗ |
| Known as | CO2 | “This randomized, double-blind, placebo-controlled, multi-center, parallel group, pilot study will evaluate the efficacy and safety of a four times a day treatment with nasal,...” NCT00917111 ↗7“S-1226 contains a potent, safe and well-tolerated bronchodilator gas (extrinsic carbon dioxide or CO2) and perflubron (PFOB), a synthetic surfactant that facilitates...” NCT04949386 ↗ “This multi-center, adaptively randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of a nasal, non-inhaled administration of carbon dioxide...” NCT00690716 ↗ “It contains a potent bronchodilator gas (carbon dioxide or CO2) and nebulized perflubron (a synthetic surfactant possessing mucolytic properties).” PMID 29914544 ↗ Jun 2018 “hand-held dispenser containing carbon dioxide (CO2 )calibrated to deliver 0.5 standard liters per minute (SLPM)” NCT02381795 ↗ “in this arm of patients, carbon dioxide (CO2) will be used for insufflation during endoscopy” NCT03287687 ↗ “Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds” NCT02113449 ↗ “extrinsic carbon dioxide or CO2” NCT04738136 ↗ |
| Modality | Other / unclassified | “Subcutaneous carbon dioxide insufflations popular in Central und Eastern Europe are a safe and inexpensive treatment modality in complementary medicine” NCT00325312 ↗ |
| Route | Subcutaneous | “Carbon dioxide gas is insufflated subcutaneously at the locations of neck muscle tenderness.” NCT00325312 ↗ |